Sunshine Heart's employees have a wealth of experience in medical technology and heart assist therapy development and commercialization.
Sunshine Heart has a world class team dedicated to commercializing the C-Pulse® System.
Chief Executive Officer; Board of Directors
Dave Rosa is Sunshine Heart's Chief Executive Officer. Mr. Rosa has spent the past 19 years in a variety of positions in the medical device industry. He was appointed CEO in October of 2009.
Prior to joining Sunshine Heart, he was President and CEO of Milksmart, Inc., a privately held company developing a unique stent-like agricultural technology that increases milking efficiencies, output and quality. From 2004-2008, Rosa was Vice President of Global Marketing for Cardiac Surgery and Cardiology at St. Jude Medical, Inc. While at St. Jude, he directed the launch of twenty seven new products within the Company's cardiovascular division.
From 1999-2004, Rosa held executive management positions at privately held A-Med Systems, Inc., an emerging medical technology company that designs, develops and commercializes percutaneously placed ventricular assist devices (pVADs) for acute heart failure. His roles included Vice President of Marketing and Sales, Senior Vice President of Marketing and Business Development, Chief Operating Officer and Chief Executive Officer. From 1995- 1999, he served as Product Manager for Angioplasty Balloons and Director of Intravascular Ultrasound at SCIMED Life Systems, a privately held company that was engaged in the development, manufacture and marketing of medical devices to treat cardiovascular disease. SCIMED was acquired by Boston Scientific Corporation and now operates as a subsidiary of Boston Scientific.
Mr. Rosa holds an M.B.A. in Marketing Management from Duquesne University and a B.S. in Commerce and Engineering from Drexel University.
William Peters, MD
Chief Technology Officer
William Peters, MD, invented the proprietary C-Pulse technology and served as Sunshine Heart’s initial CEO upon co-founding the Company in 1999. As Chief Technical Officer, he is responsible for C-Pulse’s ongoing technological development and clinical application as an innovative technology for treating moderate heart failure.
In addition to C-Pulse, Dr. Peters has developed a number of other successful cardiac technology innovations, including an endovascular cardiopulmonary bypass system for minimally invasive cardiac surgery, which was commercialized by Heartport Inc., a NASDAQ-listed company that later was acquired by Johnson & Johnson.
Dr. Peters has been the lead or co-author of more than 20 published articles, and contributed chapters to four books regarding cardiac surgery and heart failure. He has extensive clinical experience in thoracic transplantation and a variety of heart failure technologies, including intra-aortic balloon pump systems and left-ventricular assist devices (LVADs) from such companies as Biomedicus, Abiomed, Thoratec and World Heart-Novacor. He has an honorary appointments with the University of Auckland's department of surgery and biomedical engineering, providing supervision of doctoral candidates. He is also a senior clinical research fellow in cardiothoracic surgery, based at Auckland City Hospital. These roles afford Sunshine Heart a direct view of the latest developments, particularly in the fields of congestive heart failure and biomedical engineering advancement. Dr. Peters served on the board until January 2013.
Executive Vice President of Regulatory Affairs
Debra Kridner joined Sunshine Heart in November 2009 as Vice President, Clinical Research and Regulatory Affairs. Kridner brings more than 30 years of experience in clinical research, quality and regulatory affairs for the medical device industry.
Prior to joining Sunshine Heart, Kridner owned a consulting firm focused on clinical research and regulatory affairs. Before founding her own business, she served as Vice President, Clinical Research and Regulatory Affairs for Cardiac Surgery and Interventional Cardiology for the Cardiovascular Division of St. Jude Medical, Inc. Prior to St. Jude, Kridner held senior management positions in clinical, regulatory, and quality at Medtronic in the areas of cardiac surgery and neurology.
In addition Kridner also held executive management position as the Vice President of Regulatory and Quality for Medsource, an eleven facility medical device contract manufacturer. Her career also included several medical and scientific research and development companies including Edwards Lifescience/Baxter Edwards and, Gish Biomedical.
Debra is also on the Advisory Board for the St. Cloud University Masters Degree Program for Clinical Research and Regulatory Affairs. Kridner holds a B.A. in Biology from University of California Fullerton.
Chief Financial Officer
Jeff Mathiesen joined Sunshine Heart as Chief Financial Officer (CFO) in March 2011. He brings more than 20 years experience as a finance and operations officer with extensive background managing finance, manufacturing, administration, information technology, human resources, investor relations and risk management functions in diverse, publicly and privately held companies.
Prior to Sunshine Heart, Mathiesen served as Vice President and CFO for Zareba® Systems, Inc., a publicly held manufacturer and marketer of medical products, perimeter fencing and security systems. At Zareba, he helped the company change course and return to profitability, led the divestiture of two business units and helped negotiate the sale of the company to Woodstream Corp., a long-standing, privately held company.
Before Zareba® Systems, Mathiesen had served in numerous other finance and operations leadership roles in high growth, technology based, publicly held companies with operations around the globe. His experience includes several public and private equity financings including an IPO, and various M&A transactions. Previous positions held by Mathiesen include Vice President and CFO for Delphax Technologies, Inc.; Vice President of Business Development, Vice President, and CFO for Micro Component Technology, Inc.; Vice President and CFO Recovery Engineering, Inc., subsequently acquired by Proctor & Gamble; Corporate Controller at Osmonics, Inc., subsequently acquired by General Electric Company; and Aslesens, Inc., as a controller.
Mathiesen is a certified public accountant who started his career at Deloitte & Touche, LLP, after completing a B.S in Accounting at the University of South Dakota.
Senior Vice President, Clinical Affairs
Kimberly Oleson has joined Sunshine Heart in April 2014 as Senior Vice President, Clinical Affairs. Ms. Oleson brings more than 25 years of visible achievements in the medical device industry related to clinical affairs, preclinical research, quality systems and regulatory affairs.
Senior Vice President of Operations and Technology
Brian Brown joined the company in 2014 as the Senior Vice President of Technology and Operations. He brings over 24 years of experience in the medical device industry. Prior to Sunshine Heart, Brown spent 24 years at Boston Scientific in a number of leadership roles. He most recently served as the Vice President of Research and Development for the past 10 years. He participated on the executive leadership team for their Interventional Cardiology business unit, and directed the worldwide cardiovascular research and development activities. This included the launches of implantable stents, drug delivery technologies, disposable catheters, and structural heart technologies. Through active involvement with the New Business Development team Brown was also able to achieve the acquisition of numerous long term strategic technologies, which included carotid, bifurication and abluminally coated stents, along with left atrial appendage closure devices.
Vice President of Worldwide Patient Recruitment and Marketing
Molly Wade joined Sunshine Heart in October of 2013 as Senior Director of U.S. Patient Recruitment. She was appointed as Vice President, Worldwide Patient Recruitment and Marketing in August of 2014. Molly brings more than 14 years of market development and sales experience in both the medical device and pharma industries.